Influence of the angiotensin receptor blocker telmisartan on the red blood cell function and the microcirculatory perfusion

Trial Profile

Influence of the angiotensin receptor blocker telmisartan on the red blood cell function and the microcirculatory perfusion

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 27 May 2014

At a glance

  • Drugs Telmisartan (Primary)
  • Indications Hypertension
  • Focus Pharmacodynamics
  • Acronyms ITEM
  • Most Recent Events

    • 28 Jan 2009 Actual end date (Jan 2009) added as reported by ClinicalTrials.gov.
    • 28 Jan 2009 Status changed from not yet recruiting to discontinued as reported by ClinicalTrials.gov.
    • 27 Nov 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top